Multimodal cancer therapy

Last updated

Multimodal cancer therapy, often referred to simply as multimodal therapy or multimodal cancer care, is an approach for treatment of cancer that combines radiation and chemotherapy [1] or other multiple therapeutic modalities. [1] [2] For example, in the case of mesotheliomas, treatments combine modalities such as surgery, chemotherapy, immunotherapy, and radiotherapy. [3] Multimodal treatments can often have synergistic effects leading to better clinical outcomes. [4]

Contents

Diverse types of cancer can be treated via a multimodal approach, including non-small cell lung cancer [5] and gastric cancer. [6]

See also

Related Research Articles

<span class="mw-page-title-main">Esophageal cancer</span> Gastrointestinal system cancer that is located in the esophagus

Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and the stomach. Symptoms often include difficulty in swallowing and weight loss. Other symptoms may include pain when swallowing, a hoarse voice, enlarged lymph nodes ("glands") around the collarbone, a dry cough, and possibly coughing up or vomiting blood.

A radiation oncologist is a specialist physician who uses ionizing radiation in the treatment of cancer. Radiation oncology is one of the three primary specialties, the other two being surgical and medical oncology, involved in the treatment of cancer. Radiation can be given as a curative modality, either alone or in combination with surgery and/or chemotherapy. It may also be used palliatively, to relieve symptoms in patients with incurable cancers. A radiation oncologist may also use radiation to treat some benign diseases, including benign tumors. In some countries, radiotherapy and chemotherapy are controlled by a single oncologist who is a "clinical oncologist". Radiation oncologists work closely with other physicians such as surgical oncologists, interventional radiologists, internal medicine subspecialists, and medical oncologists, as well as medical physicists and technicians as part of the multi-disciplinary cancer team. Radiation oncologists undergo four years of oncology-specific training whereas oncologists who deliver chemotherapy have two years of additional training in cancer care during fellowship after internal medicine residency in the United States.

<span class="mw-page-title-main">Mesothelioma</span> Cancer associated with asbestos

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs. The area most commonly affected is the lining of the lungs and chest wall. Less commonly the lining of the abdomen and rarely the sac surrounding the heart, or the sac surrounding the testis may be affected. Signs and symptoms of mesothelioma may include shortness of breath due to fluid around the lung, a swollen abdomen, chest wall pain, cough, feeling tired, and weight loss. These symptoms typically come on slowly.

<span class="mw-page-title-main">Small-cell carcinoma</span> Type of malignant cancer

Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. Compared to non-small cell carcinoma, small cell carcinoma has a shorter doubling time, higher growth fraction, and earlier development of metastases.

<span class="mw-page-title-main">Pemetrexed</span> Chemical compound

Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

<span class="mw-page-title-main">Signet ring cell carcinoma</span> Medical condition

Signet ring cell carcinoma (SRCC) is a rare form of highly malignant adenocarcinoma that produces mucin. It is an epithelial malignancy characterized by the histologic appearance of signet ring cells.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

<span class="mw-page-title-main">HPV-positive oropharyngeal cancer</span> Cancer of the throat

Human papillomavirus-positive oropharyngeal cancer, is a cancer of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer.

<span class="mw-page-title-main">Peritoneal mesothelioma</span> Medical condition

Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This type of cancer affects the lining that protects the contents of the abdomen and which also provides a lubricating fluid to enable the organs to move and work properly.

<span class="mw-page-title-main">Treatment of cancer</span> Overview of various treatment possibilities for cancer

Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy and synthetic lethality, most commonly as a series of separate treatments. The choice of therapy depends upon the location and grade of the tumor and the stage of the disease, as well as the general state of the patient. Cancer genome sequencing helps in determining which cancer the patient exactly has for determining the best therapy for the cancer. A number of experimental cancer treatments are also under development. Under current estimates, two in five people will have cancer at some point in their lifetime.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

<span class="mw-page-title-main">Hyperthermic intraperitoneal chemotherapy</span>

Intraperitoneal hyperthermic chemoperfusion is a type of hyperthermia therapy used in combination with surgery in the treatment of advanced abdominal cancers. In this procedure, warmed anti-cancer medications are infused and circulated in the peritoneal cavity (abdomen) for a short period of time. The chemotherapeutic agents generally infused during IPHC are mitomycin-C and cisplatin.

Raja Michael Flores is an American thoracic surgeon and former candidate for mayor of New York City, currently Chief of the Division of Thoracic Surgery at Mount Sinai Hospital and Ames Professor of Cardiothoracic Surgery at the Icahn School of Medicine at Mount Sinai, both in New York City. On March 20, 2021, Dr. Flores announced his campaign for mayor of NYC.

<span class="mw-page-title-main">Nivolumab</span> Cancer drug

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein.

Interventional oncology is a subspecialty field of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using targeted minimally invasive procedures performed under image guidance. Interventional oncology has developed to a separate pillar of modern oncology and it employs X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to help guide miniaturized instruments to allow targeted and precise treatment of solid tumours located in various organs of the human body, including but not limited to the liver, kidneys, lungs, and bones. Interventional oncology treatments are routinely carried out by interventional radiologists in appropriate settings and facilities.

David John Sugarbaker was an American physician who was chief of the division of general thoracic surgery and the director of the Baylor College of Medicine Lung Institute at CHI St. Luke's Health–Baylor St. Luke's Medical Center in Houston, Texas. He was an internationally recognized thoracic surgeon specializing in the treatment of mesothelioma, the surgical management of malignant pleural mesothelioma, and treatment of complex thoracic cancers.

The host response to cancer therapy is defined as a physiological response of the non-malignant cells of the body to a specific cancer therapy. The response is therapy-specific, occurring independently of cancer type or stage.

References

  1. 1 2 Yarbro, Connie Henke; Frogge, Margaret Hansen; Goodman, Michelle (2004). Cancer Symptom Management. Jones & Bartlett Learning. p. 280. ISBN   978-0-7637-2142-8.
  2. Søreide, Kjetil; Stättner, Stefan (2021-02-04). Textbook of Pancreatic Cancer: Principles and Practice of Surgical Oncology. Springer Nature. p. 1009. ISBN   978-3-030-53786-9.
  3. Berzenji, Lawek; Van Schil, Paul (2018-10-22). "Multimodality treatment of malignant pleural mesothelioma". F1000Research. 7: F1000 Faculty Rev–1681. doi:10.12688/f1000research.15796.1. ISSN   2046-1402. PMC   6198256 . PMID   30410726.
  4. Fan, Wenpei; Yung, Bryant; Huang, Peng; Chen, Xiaoyuan (2017-11-22). "Nanotechnology for Multimodal Synergistic Cancer Therapy". Chemical Reviews. 117 (22): 13566–13638. doi:10.1021/acs.chemrev.7b00258. ISSN   0009-2665. PMID   29048884.
  5. Montemuiño Muñiz, Sara; Marcos Sánchez, Soraya; Calzas Rodríguez, Julia; Losada Vila, Beatriz; Llorente Herrero, Esther; Hisado Díaz, María Dolores; Valeri-Busto González, Victoria; Taboada Valladares, Begoña; Vaquero Barrón, Blanca; Marcos Jimenez, Francisco José; Amor Alonso, Sergio (2021-04-22). "Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer". Journal of Clinical and Translational Research. 7 (2): 185–198. ISSN   2424-810X. PMC   8177852 . PMID   34104821.
  6. Proserpio, Ilaria; Rausei, Stefano; Barzaghi, Sabrina; Frattini, Francesco; Galli, Federica; Iovino, Domenico; Rovera, Francesca; Boni, Luigi; Dionigi, Gianlorenzo; Pinotti, Graziella (2014-04-27). "Multimodal treatment of gastric cancer". World Journal of Gastrointestinal Surgery. 6 (4): 55–58. doi:10.4240/wjgs.v6.i4.55. ISSN   1948-9366. PMC   4013710 . PMID   24829622.

Citations